Surrozen Inc (SRZN) - Total Liabilities
Based on the latest financial reports, Surrozen Inc (SRZN) has total liabilities worth $398.86 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Surrozen Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Surrozen Inc's total liabilities have evolved over time, based on quarterly financial data. See Surrozen Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Surrozen Inc Competitors by Total Liabilities
The table below lists competitors of Surrozen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alliance Entertainment Holding Corporation Class A Common Stock
NASDAQ:AENT
|
USA | $267.15 Million |
|
Koramco Energy Plus Reit Co Ltd
KO:357120
|
Korea | ₩781.19 Billion |
|
Liaoning SG Automotive Group Co Ltd
SHG:600303
|
China | CN¥2.21 Billion |
|
Anhui Huangshan Capsule Co Ltd
SHE:002817
|
China | CN¥137.27 Million |
|
LAVIPHARM S.A. NA EO 1
F:BXA0
|
Germany | €72.52 Million |
|
Baiyang Aquatic Group Inc
SHE:002696
|
China | CN¥2.54 Billion |
|
Kaplamin Ambalaj Sanayi ve Ticaret AS
IS:KAPLM
|
Turkey | TL701.17 Million |
|
Biostar Microtech International Corp
TW:2399
|
Taiwan | NT$636.03 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Surrozen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Surrozen Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Surrozen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Surrozen Inc (2019–2025)
The table below shows the annual total liabilities of Surrozen Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $286.49 Million | +310.17% |
| 2024-12-31 | $69.85 Million | +757.54% |
| 2023-12-31 | $8.14 Million | -39.37% |
| 2022-12-31 | $13.43 Million | -51.10% |
| 2021-12-31 | $27.47 Million | +86.05% |
| 2020-12-31 | $14.77 Million | +12.73% |
| 2019-12-31 | $13.10 Million | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more